COVID-19: Guidance for the Management of Adult Rheumatology Patients

This question is drawn from "ACR Releases COVID-19 Clinical Guidance," The Rheumatologist.

For rheumatic disease treatment in the context of documented or presumptive COVID-19 infection, which of the following statements is false?

A. Regardless of COVID-19 severity, antimalarial therapies (hydroxychloroquine or chloroquine) may be continued.

B. Sulfasalazine, methotrexate, leflunomide, immunosuppressants, non-IL-6 biologics and JAK inhibitors should be stopped or held.

C. For patients with severe respiratory symptoms, NSAIDs should be continued.

D. IL-6 inhibitors may be continued.